Share This Page
Drugs in ATC Class C04AB
✉ Email this page to a colleague
Drugs in ATC Class: C04AB - Imidazoline derivatives
| Tradename | Generic Name |
|---|---|
| ORAVERSE | phentolamine mesylate |
| PHENTOLAMINE MESYLATE | phentolamine mesylate |
| REGITINE | phentolamine mesylate |
| RYZUMVI | phentolamine mesylate |
| >Tradename | >Generic Name |
Showing 1 to 4 of 4 entries
C04AB Market Analysis and Financial Projection
The global market for ATC Class C04AB imidazoline derivatives is experiencing steady growth, driven by therapeutic applications in hypertension, cardiovascular diseases, and targeted drug development. Concurrently, the patent landscape highlights innovation in synthesis methods and expanded clinical uses. Below is a detailed analysis of market dynamics and intellectual property trends.
Market Dynamics
Growth Projections and Drivers
- The imidazoline derivative inhibitor market was valued at USD 1.29 billion in 2024, with a projected compound annual growth rate (CAGR) of 5.5% through 2034, reaching USD 2.20 billion[1][8]. Alternative forecasts suggest a slightly higher CAGR of 6.3%, aiming for USD 2.51 billion by 2029[3][15].
- Key drivers include:
- Rising prevalence of hypertension, diabetes, and neurological disorders[1][11].
- Advancements in targeted therapies and personalized medicine, particularly in oncology and metabolic diseases[1][8].
- Increased R&D investments by pharmaceutical giants like Pfizer, Merck, and Novartis to develop derivatives with enhanced efficacy and reduced side effects[1][8].
Regional Insights
- North America dominates the market (largest share in 2024), attributed to advanced healthcare infrastructure and high chronic disease rates[8].
- Asia-Pacific is the fastest-growing region, driven by industrialization, expanding pharmaceutical sectors in China and India, and rising healthcare investments[3][8].
Competitive Landscape
- Major players focus on strategic collaborations and bio-based derivatives to address production challenges and environmental concerns[3][14].
- Trends include nanotechnology integration for improved drug delivery and AI-driven drug discovery to optimize therapeutic profiles[3][8].
Patent Landscape
Key Innovations and Patents
-
Synthesis Methods:
- US3966757A (1968): Covers 2-[α-(2,6-dichlorophenoxy)-ethyl]-imidazoline, a compound with anti-hypertensive properties, synthesized via aryloxy carboxylic acid reactions[5].
- CN102093296B (2010): Describes a method to reduce diamide impurities during imidazoline production, improving stability and scalability[14].
- EP0378910A1 (1983): Focuses on catalytic dehydrogenation of imidazolines to create imidazoles for use in epoxy resins and surfactants[10].
-
Therapeutic Expansions:
- WO2010123150A1 (2010): Introduces 2-aryl imidazoline derivatives as GPR103 receptor antagonists for treating obesity and metabolic disorders[16].
- Tolazoline (C04AB02): A vasodilator with patents covering its use in peripheral vascular diseases and as an antihypertensive agent[17].
Challenges and Trends
- Production Complexity: Early patents highlight issues like byproduct formation (e.g., diamides), addressed in newer synthesis techniques[5][14].
- Emerging Applications: Recent patents explore imidazolines in neuroprotection, anticancer therapies, and antimicrobial agents[11][16].
- Geographical Shifts: While the U.S. and Europe lead in historical filings, China is emerging as a hub for cost-effective synthesis methods[14].
Future Outlook
- Market Opportunities: Growth in bio-based inhibitors and sustainable production methods aligns with environmental regulations[3][14].
- Patent Strategies: Companies are prioritizing combination therapies (e.g., imidazolines with immune checkpoint inhibitors) and nanocarrier systems to enhance drug delivery[2][8].
Highlight: "The development of novel imidazoline derivatives with improved therapeutic profiles is critical to addressing unmet medical needs in chronic disease management." — Polaris Market Research[8].
The convergence of robust market demand and innovative patent activity positions imidazoline derivatives as a pivotal class in cardiovascular and metabolic therapeutics.
References
- https://www.globenewswire.com/news-release/2024/12/12/2995987/0/en/Imidazoline-Derivative-Inhibitor-Market-Share-to-Rise-At-5-5-CAGR-To-Surpass-USD-2-20-Billion-by-2034-PMR.html
- https://www.businesswire.com/news/home/20250224366580/en/Bispecific-Antibody-and-Cancer-Patent-Landscape-Analysis-2025-with-IP-Profiles-of-Key-Players-Amgen-Genentech-Roche-GenMab-Janssen-Regeneron-and-Xencor---ResearchAndMarkets.com
- https://www.openpr.com/news/3869263/imidazoline-derivative-inhibitor-market-poised-for-6-3
- https://www.healthybelgium.be/en/medical-practice-variations/medications/cross-system-analyses/polypharmacy-65-years-and-older?highlight=WyJmb3IiLCJwZXJmb3JtYW5jZSIsImNvbmZvcm1pdFx1MDBlOSIsImZvcmNcdTAwZTltZW50IiwiZm9ybWUiLCJmb3J0ZW1lbnQiLCJpbmZvcm1hdGlvbnMiLCJpbmZvcm1hdGlvbiIsImZvcmVuc2lzY2hlIiwiZm9ybWluZyJd
- https://patents.google.com/patent/US3966757A/en
- https://go.drugbank.com/categories/DBCAT002448
- https://www.globenewswire.com/news-release/2025/03/14/3043095/0/en/Comprehensive-Near-Infrared-Spectroscopy-Patent-Landscape-Report-Reveals-Market-to-Reach-USD-989-8-Million-by-2032.html
- https://www.polarismarketresearch.com/industry-analysis/imidazoline-derivative-inhibitor-market
- https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/nvNsI8S7K9U.pdf
- https://patents.google.com/patent/EP0378910A1/en
- https://pubmed.ncbi.nlm.nih.gov/33031924/
- https://en.wikipedia.org/wiki/ATC_code_C04
- https://data.epo.org/publication-server/rest/v1.1/patents/EP0002943NWA1/document.html
- https://patents.google.com/patent/CN102093296B/en
- https://www.verifiedmarketresearch.com/product/imidazoline-derivative-inhibitor-market/
- https://patents.google.com/patent/WO2010123150A1/en
- https://www.pharmakb.com/drug-report/tolazoline
- https://www.transparencymarketresearch.com/peripheral-vasodilator-drugs-market.html
- https://atcddd.fhi.no/atc_ddd_index/?code=C04A&showdescription=no
More… ↓
